TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11221017

Group type: EXPERIMENTAL
Intervention: irinotecan alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: irinotecan in combination with cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: irinotecan vs vindesine/cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: irinotecan/cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: weekly irinotecan with weekly cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: irinotecan/paclitaxel/carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: irinotecan/docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cisplatin or irinotecan in combination with docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: irinotecan and gemcitabine
Number of subjects: 0
Study: 9627292

Group type: EXPERIMENTAL
Intervention: Goserelin plus HRT
Number of subjects: 42

Group type: COMPARATOR
Intervention: Goserelin alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: HRT1 and HRT2 groups
Number of subjects: 42

Group type: COMPARATOR
Intervention: HRT0 group
Number of subjects: 42
Study: 8149803

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with pre-peritoneal implantation of a prosthetic mesh
Number of subjects: 250
Study: 3382587

Group type: EXPERIMENTAL
Intervention: Alfuzosin 5 mg twice daily for 7 days
Number of subjects: 6
Study: 30659559

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 148
Study: 27697703

Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenge
Number of subjects: 25
Study: 24915259

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula
Number of subjects: 2159

Group type: COMPARATOR
Intervention: Conventional cows' milk‐based formula
Number of subjects: 2159
Study: 21846665

Group type: EXPERIMENTAL
Intervention: Parent education sessions and coaching sessions
Number of subjects: 0
Study: 20840231

Group type: EXPERIMENTAL
Intervention: Experimental group received a program aimed at improving representation and transformation of visuospatial information.
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group received a substitute program.
Number of subjects: 116
Study: 17526436

Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS
Number of subjects: 102

Group type: COMPARATOR
Intervention: ICBG
Number of subjects: 102
Study: 15891633

Group type: EXPERIMENTAL
Intervention: Radiofrequency tympanostomy (Group B)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Radiofrequency tympanostomy with topical mitomycin C application (Group C)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cold knife myringotomy (Group A)
Number of subjects: 96
Study: 11982640

Group type: EXPERIMENTAL
Intervention: Combination of a single-strain Leishmania amazonensis killed promastigote vaccine plus a half dose of meglumine antimoniate.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo plus half dose of meglumine antimoniate.
Number of subjects: 102
Study: 10553612

Group type: EXPERIMENTAL
Intervention: Case management services
Number of subjects: 8248

Group type: COMPARATOR
Intervention: Control group (nonparticipants)
Number of subjects: 8248
Study: 8684633

Group type: EXPERIMENTAL
Intervention: NLA in N2O-O2
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl in air-O2
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 64
Study: 2195136

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) + leucovorin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil (5FU) alone
Number of subjects: 0
Study: 7461567

Group type: EXPERIMENTAL
Intervention: Benzbromarone-citrate combination (Harolan)
Number of subjects: 21
Study: 31470443

Group type: EXPERIMENTAL
Intervention: Two horizontally aligned pins (H)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Two vertically aligned pins (V)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Two horizontally aligned pins with a tension band wire (H-TB)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Two vertically aligned pins with a tension band wire (V-TB)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no tension band)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tension band (TB) constructs
Number of subjects: 18
Study: 30611202

Group type: EXPERIMENTAL
Intervention: Laryngoscope-guided insertion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Blind insertion
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 26847527

Group type: EXPERIMENTAL
Intervention: Physiotherapeutic intervention including daily training program with movements to increase chest flexibility, breathing exercises, and relaxation sessions.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Physiotherapeutic intervention
Number of subjects: 41
Study: 25756412

Group type: COMPARATOR
Intervention: IV propofol (n = 74)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Inhaled volatile anesthetic agents (isoflurane or sevoflurane) (n = 67)
Number of subjects: 141
Study: 23815747

Group type: EXPERIMENTAL
Intervention: TAP block (20 mL of either 0.375% ropivacaine or 0.3% levobupivacaine)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (epidural morphine 2 mg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: TAP block (local anesthetics)
Number of subjects: 94
Study: 20391324

Group type: EXPERIMENTAL
Intervention: Valgus knee brace (M4 OA®, Medi) applied for 2-4 hours per day during activity (n = 13)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Elastic knee bandage (Genumedi®, Medi) applied for 2-4 hours per day during activity (n = 10)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (untreated individuals) (n = 10)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Valgus knee brace (M4 OA®, Medi)
Number of subjects: 33
Study: 18992248

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 538

Group type: COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Number of subjects: 538
Study: 16895944

Group type: EXPERIMENTAL
Intervention: Immediate computed tomography
Number of subjects: 2602

Group type: COMPARATOR
Intervention: Admission for observation
Number of subjects: 2602

Group type: EXPERIMENTAL
Intervention: Immediate computed tomography and Admission for observation
Number of subjects: 2602
Study: 14984497

Group type: EXPERIMENTAL
Intervention: Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) 200 microg/m2
Number of subjects: 110

Group type: COMPARATOR
Intervention: No GM‐CSF
Number of subjects: 110
Study: 11354565

Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization
Number of subjects: 267
Study: 9507791

Group type: EXPERIMENTAL
Intervention: Cortisol
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: NPY
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Family history of hypertension
Number of subjects: 179
Study: 7999177

Group type: EXPERIMENTAL
Intervention: DEU rotation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 3370986

Group type: EXPERIMENTAL
Intervention: K salt supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potassium blocker (triamterene)
Number of subjects: 0
Study: 30209712

Group type: EXPERIMENTAL
Intervention: Hand massage (7 sessions over 3 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no hand massage)
Number of subjects: 40
Study: 27213725

Group type: EXPERIMENTAL
Intervention: Exposure to multiple individuals exhibiting within-person variability in facial emotion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure to multiple individuals exhibiting a single facial emotion
Number of subjects: 0
Study: 25686299

Group type: EXPERIMENTAL
Intervention: Paravertebral Block (PVB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 40
Study: 21486110

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 21573941

Group type: EXPERIMENTAL
Intervention: Red pepper (150 mg of red pepper powder, 4 pills/day for 6 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Red pepper
Number of subjects: 50
Study: 18065406

Group type: EXPERIMENTAL
Intervention: CAPIRI + celecoxib (C)
Number of subjects: 85

Group type: COMPARATOR
Intervention: CAPIRI + placebo (P)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: FOLFIRI + celecoxib (C)
Number of subjects: 85

Group type: COMPARATOR
Intervention: FOLFIRI + placebo (P)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: CAPIRI
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: celecoxib
Number of subjects: 85

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 85
Study: 16501249

Group type: EXPERIMENTAL
Intervention: WRN Cys1367Arg polymorphism
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: p53 MspI 1798G>A (16 bp insertion/duplication)
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Joint effect of WRN Cys1367Arg and p53 MspI
Number of subjects: 1828
Study: 14665655

Group type: EXPERIMENTAL
Intervention: C-reactive protein levels (measured at baseline)
Number of subjects: 20525
Study: 10893594

Group type: EXPERIMENTAL
Intervention: 10 cc of 2% intrarectal lidocaine 10 minutes before the procedure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 8883009

Group type: EXPERIMENTAL
Intervention: Inosine supplementation (5,000 mg.day‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1547685

Group type: EXPERIMENTAL
Intervention: GLP‐I‐(7‐37) infusion (1‐5 ng.kg‐1.min‐1 for 30 min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GLP‐I‐(7‐37) infusion concurrent with a standard meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GLP‐I‐(7‐37) infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 15
Study: 3524234

Group type: EXPERIMENTAL
Intervention: Fetal acoustic stimulation test (transabdominal acoustic stimulation with a Model 5C electronic artificial larynx)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonstress test (control group)
Number of subjects: 100
Study: 30140006

Group type: EXPERIMENTAL
Intervention: LPS injection
Number of subjects: 22
Study: 27032570

Group type: EXPERIMENTAL
Intervention: High monetary incentive
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low monetary incentive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anger primes
Number of subjects: 0
Study: 25831646

Group type: EXPERIMENTAL
Intervention: Aspiration and injection treatment (Triamcinolone acetonide)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Surgical excision
Number of subjects: 173

Group type: COMPARATOR
Intervention: Comparison of failure rates
Number of subjects: 173
Study: 23355624

Group type: COMPARATOR
Intervention: Top quartile hospitals (high ICU admission)
Number of subjects: 166224

Group type: EXPERIMENTAL
Intervention: Other hospitals (lower ICU admission)
Number of subjects: 166224

Group type: EXPERIMENTAL
Intervention: Overall HF in-hospital risk-standardized mortality
Number of subjects: 166224
Study: 21176524

Group type: EXPERIMENTAL
Intervention: 10 µg recombinant CHO hepatitis B vaccine
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: 20 µg recombinant CHO hepatitis B vaccine
Number of subjects: 642
Study: 18655742

Group type: EXPERIMENTAL
Intervention: Transcutaneous carbon dioxide pressure monitoring (P(tcCO(2))) during daytime spontaneous breathing trials (SBTs)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Transcutaneous carbon dioxide pressure monitoring (P(tcCO(2))) during first nights off the ventilator
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Transcutaneous carbon dioxide pressure monitoring (P(tcCO(2))) during bronchoscopy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Comparison of P(tcCO(2)) and P(aCO(2))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Comparison of P(aCO(2)) and P(ETCO(2))
Number of subjects: 15
Study: 20092773

Group type: EXPERIMENTAL
Intervention: No drain (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: With drain (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 100
Study: 15685823

Group type: EXPERIMENTAL
Intervention: Gemcitabine (800 mg/m2 days 1 and 8), Epirubicin (90 mg/m2 day 1), Docetaxel (75 mg/m2 day 1) with prophylactic filgrastim (Neupogen)
Number of subjects: 77
Study: 12575551

Group type: EXPERIMENTAL
Intervention: Combined medication of Songling Xue-maikang Capsule (SXC) with captopril
Number of subjects: 166

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 166
Study: 9456419

Group type: EXPERIMENTAL
Intervention: Topical and subconjunctival anesthesia with lidocaine 4%
Number of subjects: 402

Group type: COMPARATOR
Intervention: Retrobulbar injection of lidocaine 4%
Number of subjects: 402
Study: 7943774

Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg (M high)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lorazepam 0.1 mg/kg (L high)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 3285830

Group type: EXPERIMENTAL
Intervention: 20 mg torasemide
Number of subjects: 19

Group type: COMPARATOR
Intervention: 40 mg furosemide
Number of subjects: 19
Study: 31076850

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 31470366

Group type: EXPERIMENTAL
Intervention: Royal jelly (1000 mg daily for eight weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 28068681

Group type: EXPERIMENTAL
Intervention: Hypoxia (≈14 vol%O2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Normoxia (≈21 vol%O2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypoxia/Hyperoxia (≈14 vol%O2/≈30 vol%O2, 5‐min intervals)
Number of subjects: 9
Study: 25611825

Group type: EXPERIMENTAL
Intervention: Therapist ratings of resistance
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Observer ratings of resistance
Number of subjects: 40
Study: 23887843

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 5515
Study: 21914281

Group type: EXPERIMENTAL
Intervention: Shenfu (SF) injection administered by peripheral intravenous infusion at initially 0.2 ml/kg and then 0.8 ml×kg(‐1)×h(‐1) until the end of operations
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline administered similarly to Group S
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Shenfu (SF) injection
Number of subjects: 24
Study: 19995250

Group type: EXPERIMENTAL
Intervention: Reduction mammaplasty (surgery)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conservative treatment (control)
Number of subjects: 82
Study: 17468908

Group type: EXPERIMENTAL
Intervention: D-Stat Dry bandage as an adjunct to manual compression
Number of subjects: 376

Group type: COMPARATOR
Intervention: Manual compression alone
Number of subjects: 376
Study: 15269068

Group type: EXPERIMENTAL
Intervention: Nurse led clinic (NLC)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Consultant led paediatric gastroenterology clinic (PGC)
Number of subjects: 102
Study: 11316648

Group type: EXPERIMENTAL
Intervention: He‐O2 gas mixture (79% He, 21% O2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 10
Study: 9228270

Group type: EXPERIMENTAL
Intervention: Power Doppler (p‐TCCS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Colour Doppler frequency imaging mode (f‐TCCS)
Number of subjects: 12
Study: 8076711

Group type: EXPERIMENTAL
Intervention: L-arginine supplementation (30 g/day for 3 days prior to each course of chemotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHOP chemotherapy only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-arginine supplementation
Number of subjects: 0
Study: 3111144

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (non-splenectomised CLL patients)
Number of subjects: 20
Study: 29545253

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of bone marrow-derived mononuclear cells
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no stem cell infusion)
Number of subjects: 20
Study: 27276739

Group type: EXPERIMENTAL
Intervention: Isomaltulose (ISO) breakfast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sucrose (SUC) breakfast
Number of subjects: 0
Study: 23324726

Group type: EXPERIMENTAL
Intervention: 24-week aerobic exercise intervention
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study: 22898557

Group type: EXPERIMENTAL
Intervention: PsA‐TT (MenAfriVac™)
Number of subjects: 340

Group type: COMPARATOR
Intervention: PsACWY (Mencevax ACWY(®))
Number of subjects: 340
Study: 20351589

Group type: EXPERIMENTAL
Intervention: 5-week exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-week exercise intervention (l allele carriers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-week exercise intervention (ss individuals)
Number of subjects: 0
Study: 18657684

Group type: EXPERIMENTAL
Intervention: Fast ForWord (FFW, experimental group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: SuccessMaker (SM, active control group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: FFW followed by SM
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: SM followed by FFW
Number of subjects: 65

Group type: COMPARATOR
Intervention: No intervention beyond the regular class curriculum (developmental control group)
Number of subjects: 65
Study: 15935432

Group type: EXPERIMENTAL
Intervention: Ethanol infusion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 12500933

Group type: EXPERIMENTAL
Intervention: Physiotherapy Management Care Plan (PMCP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Exercise instruction booklet (Control Group)
Number of subjects: 65
Study: 9457834

Group type: EXPERIMENTAL
Intervention: 12 Gy/2 fractions (group A)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 16 Gy/2 fractions (group B)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 18 Gy/3 fractions (group C)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Fractionated brachytherapy
Number of subjects: 172
Study: 7641062

Group type: EXPERIMENTAL
Intervention: Fructose (F)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Glucose + Arginine + Citric Acid (GAC)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 2666484

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TS) patch
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 10
Study: 1093308

Group type: EXPERIMENTAL
Intervention: Flavoxate
Number of subjects: 382

Group type: COMPARATOR
Intervention: Phenazopyridine
Number of subjects: 382
Study: 28567530

Group type: EXPERIMENTAL
Intervention: Immediate definitive individualized abutments (T)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control individualized abutments (C)
Number of subjects: 16
Study: 27707817

Group type: EXPERIMENTAL
Intervention: evolocumab 420 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: evolocumab 140 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 24130144

Group type: EXPERIMENTAL
Intervention: Camel Snus (Snus to Cope)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Camel Snus (Snus to Reduce)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No-supply group (Control)
Number of subjects: 57
Study: 22751965

Group type: EXPERIMENTAL
Intervention: Individual withdrawal with restricted symptomatic medication and prophylactics from Day 1 (Group A)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Two-month drug-free period with multidisciplinary education in groups (Group B)
Number of subjects: 98
Study: 20378841

Group type: EXPERIMENTAL
Intervention: 2.27% glucose-based PET
Number of subjects: 90

Group type: COMPARATOR
Intervention: 3.86% glucose-based PET
Number of subjects: 90
Study: 18691293

Group type: EXPERIMENTAL
Intervention: Specific Immunotherapy (SIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 15911192

Group type: EXPERIMENTAL
Intervention: Poster campaign in Geneva (exposed group)
Number of subjects: 1955

Group type: COMPARATOR
Intervention: Control group in Neuchatel
Number of subjects: 1955

Group type: COMPARATOR
Intervention: Comparison of before-after change between Geneva and Neuchatel
Number of subjects: 1955

Group type: EXPERIMENTAL
Intervention: Poster campaign
Number of subjects: 1955
Study: 12891212

Group type: EXPERIMENTAL
Intervention: Pioglitazone (23 patients with 23 lesions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (21 patients with 21 lesions)
Number of subjects: 44
Study: 11273876

Group type: EXPERIMENTAL
Intervention: Folic acid (15 mg intravenously three times weekly)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Folinic acid (16.1 mg intravenously three times weekly)
Number of subjects: 66
Study: 9126714

Group type: EXPERIMENTAL
Intervention: Intervention group (participants)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (non-participants)
Number of subjects: 73
Study: 8247194

Group type: EXPERIMENTAL
Intervention: Sublingual captopril (25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sublingual prazosin (2 mg)
Number of subjects: 0
Study: 3930305

Group type: EXPERIMENTAL
Intervention: 6 capsules of carotenoids (10 mg beta‐carotene + 15 mg canthaxanthin per capsule)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 4 capsules of carotenoids (10 mg beta‐carotene + 15 mg canthaxanthin per capsule)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups (4 and 6 capsules)
Number of subjects: 14
Study: 31012803

Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Choline-Magnesium
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Choline
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 29901456

Group type: EXPERIMENTAL
Intervention: Electrocautery ablation (ECA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Argon plasma coagulation (APC)
Number of subjects: 49